Study of liver cancer that comes back after surgery
Part of Cancer, Digestive system clinical trials.
This trial is studying people with liver cancer (hepatocarcinoma) whose cancer returns (recurs) or never fully goes away (persists) after surgery. It looks at patterns after treatment at a specific study center, which may help guide better care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocarcinoma, confirmed by a tissue sample (biopsy or surgery specimen)
- Your first liver cancer diagnosis, or its return/persistence, was assessed and treated with surgery at the study center
- Your evaluation for joining the study began on or after 02/02/2019
- Your surgery was not done only to “downstage” the cancer before a liver transplant
- Your surgery was done with curative intent (not just to ease symptoms or provide supportive care)
- Your tumor was not a mixed cancer type like hepatocholangiocarcinoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test that tracks circulating tumor cells (CTCs) can help doctors detect early signs of liver cancer returning after surgery. It aims to give patients and their doctors a better way to monitor for recurrence.
This trial compares surgery against active monitoring for patients whose liver cancer shrank or disappeared after initial treatments. The goal is to determine which approach offers better outcomes for those who have had a good response to therapy.
This study checks whether a blood test that looks for leftover cancer DNA (ctDNA) after surgery can predict if your liver cancer will come back. It compares that test result with what doctors find in the removed tumor tissue.
This trial studies patients with liver cancer, including both the common type (hepatocellular carcinoma) and other types. It aims to understand the cancer better by collecting blood samples and medical information.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.